Selectimmune Pharma AB (publ) reported earnings results for the third quarter and nine months ended March 31, 2022. For the third quarter, the company reported revenue was SEK 0.007472 million compared to SEK 0.007768 million a year ago. Net loss was SEK 3.49 million compared to SEK 2.36 million a year ago. Basic loss per share from continuing operations was SEK 0.1998 compared to SEK 0.1353 a year ago.
For the nine months, revenue was SEK 0.007472 million compared to SEK 0.007991 million a year ago. Net loss was SEK 11.12 million compared to SEK 7.58 million a year ago. Basic loss per share from continuing operations was SEK 0.6368 compared to SEK 0.4341 a year ago.